• slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • slidebg1
  • 20
    10/17
    NEWS
    Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics...
    Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A...
  • PRESS RELEASE
    The Chiesi Group is one of the 8 Italian companies invited by Macron to the...
    Versailles (France), January 22, 2018 - The Chiesi Group, represented by the CEO Ugo Di Francesco, took part yesterday at the...